Authors

Martin Moorhead, PhD

Latest:

Martin Moorhead on Role of Minimal Residual Disease in Leukemia and Lymphoma

Martin Reck, MD

Latest:

Dr. Reck on Updated Results of the CheckMate 9LA Trial in Advanced NSCLC

Martin Reck, MD, PhD, discusses updated results of the phase 3 CheckMate 9LA study in advanced non–small cell lung cancer.

Martin Reck, MD, PhD, Lung Clinic Grosshansdorf

Latest:

Rapid Readouts: CheckMate 9LA

Martin Reck, MD, PhD, Hospital Grosshansdorf

Martin S. Tallman, MD

Latest:

Dr. Tallman on FDA Approval of Midostaurin in AML

Martin S. Tallman, MD, chief, Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of midostaurin (PKC412) for adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).

Martin S. Tallman, MD, Memorial Sloan Kettering Cancer Center

Martin Schlumberger, MD

Latest:

Dr. Schlumberger Draws Conclusions From the SELECT Trial in Thyroid Cancer

Martin Schlumberger, MD, Institut Gustave Roussy, Villejuif Cedex, professor of oncology, University Paris-Sud, France, discusses the takeaway points for a community oncologist from the SELECT trial.

Martin van den Bent, MD, PhD

Latest:

Dr. van den Bent on Next Steps for ABT-414 in Brain Cancer

Martin J. van den Bent, MD, &lrm;Head Neuro-Oncology Unit at Erasmus MC Cancer Center, discusses what the next trials will be for ABT-414, anti-EGFR antibody-drug conjugate under exploration for patients with brain cancer.

Martina Weise, MD

Latest:

Dr. Weise Discusses the Future of Biosimilars in Oncology

Martina Weise, MD, head of Division Licensing 2, and German CHMP member of the Federal Institute for Drugs and Medical Devices, discusses the future of biosimilars in oncology.

Martine J. Piccart, MD, PhD

Latest:

Dr. Piccart on Personalized Care for Breast Cancer

Martine J. Piccart, MD, PhD, professor, Université Libre de Bruxelles, director, Medicine Department, Institut Jules Bordet, discusses personalized care for patients with breast cancer.

Martine Piccart, MD, PhD

Latest:

Dr. Piccart Discusses Biomarkers in Early Breast Cancer

Martine J. Piccart, MD, PhD, professor, Université Libre de Bruxelles, director, Medicine Department, Institut Jules Bordet, discusses biomarkers in early breast cancer.

Marwan Fakih, MD

Latest:

Future Outlooks in the Treatment of Metastatic Colorectal Cancer

Experts discuss their vision for the future of colorectal cancer treatment and anticipated advancements in the field.

Marwan Fakih, MD, City of Hope

Marwan Fakih, MD, City of Hope Comprehensive Cancer Center

Marwan Fakih, MD, City of Hope Comprehensive Care Center

Marwan G. Fakih, MD

Latest:

Dr Fakih on OS Data for Sotorasib Plus Panitumumab in KRAS G12C+ mCRC

Marwan G. Fakih, MD, discusses data for sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.

Marwan G. Fakih, MD, City of Hope

Latest:

Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment

Panelists discuss the frequency of hypertension observed with trifluridine-tipiracil plus bevacizumab and their strategies for monitoring and managing it, as well as their approach to dosing TAS-102 plus bevacizumab in patients with hepatic or renal impairment. They also review common toxicities associated with fruquintinib and regorafenib, including hypertension, hand-foot syndrome, and hepatotoxicity, and share management strategies for these adverse events.

Mary Caffrey

Latest:

Multiple Factors Contribute to Disparities in Health and Cancer Outcomes

The issue of disparities in cancer is multifactorial, as it can cover not only race, ethnic, and cultural issues, but also gender identification.

Mary Chamberlin, MD

Latest:

As the Global Burden of Cancer Rises, Can Fellowship Training Adapt?

As a fellowship director, Mary Chamberlin, MD, needed to adopt a new mind-set when training her fellows from low-income countries.

Mary-Ellen Taplin, MD

Latest:

Dr Taplin on Health Care Inequities in Prostate Cancer Treatment

Mary-Ellen Taplin, MD, discusses strategies to mitigate health care inequities in prostate cancer.